- Article
- Source: Campus Sanofi
- May 19, 2025
SoliMix Study Results Summary
Discover clinical outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial leading to advancing therapy in sub-optimally controlled basal insulin-treated Type-2 diabetes.
MAT-BH-2300623/v1/November2023